Enanta Pharmaceuticals: Holding Ahead of Some Key Events
Long Ideas - Since our July 24 report on Enanta Pharmaceuticals (ENTA), shares of the HCV company have risen over 15%, even after accounting for the sell-off in … Continue Reading
Read NowLong Ideas
Medivation Chalks Up a Win but Market Hesitates
Long Ideas - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read NowEveryone’s Piling Back Into Equities: Here’s Where PropThink is Involved
Long Ideas - Tekmira Pharmaceuticals (TKMR) announced a secondary offering on Wednesday and priced the deal before Thursday’s open. Tekmira is selling 3,750,000 common stock at a price … Continue Reading
Read NowTekmira Raises Money
Long Ideas - Editor’s Note: A version of this commentary was sent to PropThink Premium subscribers on the morning of Thursday, October 17. On Friday the 18th, TKMR … Continue Reading
Read NowWhy Zerenex Could Be More than Just a Dialysis Product
Long Ideas - Early this year, Keryx Biopharmaceuticals (KERX) reported strong Phase III results for its phosphate binder Zerenex (ferric citrate) in dialysis patients, sending the stock from … Continue Reading
Read NowInvestors Overdid the Endocyte Sell-Off
Long Ideas - With the stock down 20% in early morning trading on Friday, October 11, PropThink wrote to PropThink Premium subscribers that Endocyte’s (ECYT) weakness offered another buying opportunity … Continue Reading
Read NowBIND Therapeutics Had a Muted IPO but the Thesis Intrigues
Long Ideas - 2013 has been a banner year for biotech IPO’s, with a number of companies making their public debuts to strong reception by the market. BIND … Continue Reading
Read Now